Nucleai Launches New Multiplex Imaging Spatial Analysis Solution to Increase Reliability and Speed of Immunofluorescence Analysis for Drug Discovery and Development

Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of mIF data for drug discovery and development. Nucleai will present new data demonstrating the power of its new mIF pipeline to correlate spatial features with patient outcomes in colorectal cancer (CRC) at the Society for Immunotherapy of Cancer (SITC) conference in Boston this week.

Contact us

Unsubscribe at any time using the link in our emails.
For details, see our Privacy Policy.

Add Your Heading Text Here